REZUROCK (belumosudil) tablets logo

For US Health Care
Professionals Only

REZUROCK (belumosudil) tablets logo

For US Health Care
Professionals Only

Full Prescribing
Information CONNECT WITH A REPRESENTATIVE

An innovative way to treat cGVHD1-3

For patients with cGVHD aged ≥12 years after failure of any 2 prior lines of systemic therapy.1
For patients with cGVHD aged ≥12 years after failure of any 2 prior lines of systemic therapy.1
rezurock can help patients

ROCK ON

REZUROCK is the first and only treatment for cGVHD that selectively inhibits the rock2 pathway. REZUROCK is an immunomodulator that is designed to downregulate inflammation and fibrosis.1-3

REZUROCK is the first and only treatment for cGVHD that selectively inhibits the rock2 pathway. REZUROCK is an immunomodulator that is designed to downregulate inflammation and fibrosis.1-3

Belumosudil (REZUROCK®) has been added to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) as a category 2A systemic option for steroid-refractory cGVHD.4,a

REZUROCK demonstrated efficacy in a broad range of patients with cGVHD1

The ORRb,c was 75% at the recommended dose of 200 mg once daily (n=65) in the pivotal ROCKstar study.

EXPLORE EFFICACY

The safety of REZUROCK was evaluated across 2 multicenter clinical studies1

REZUROCK was evaluated in a real-world population of patients with cGVHD.
 

EXPLORE Safety
and tolerability

aNCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

bBased on a final analysis by the FDA (n=65).

cProportion of patients who achieved CR or PR according to the 2014 NIH cGVHD Consensus Criteria.1

aNCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

bBased on a final analysis by the FDA (n=65).

cProportion of patients who achieved CR or PR according to the 2014 NIH cGVHD Consensus Criteria.1

A ROCK2 inhibitor designed to address the

Inflammation and fibrosis

associated with cGVHD1-3

See How REZUROCK works Discover AN INNOVATIVE
dual inhibitor See How REZUROCK works Discover AN INNOVATIVE
dual inhibitor

cGVHD, chronic graft-versus-host disease; FDA, US Food and Drug Administration; MOA, mechanism of action; NCCN, National Comprehensive Cancer Network®; ORR, overall response rate; ROCK2, rho-associated coiled-coil—containing protein kinase-2.

References: 1. REZUROCK. Package insert. Kadmon Pharmaceuticals, LLC; 2023. 2. Zanin-Zhorov A, Weiss JM, Nyuydzefe MS, et al. Selective oral ROCK2 inhibitor down-regulates IL-21 and IL-17 secretion in human T cells via STAT3-dependent mechanism. Proc Natl Acad Sci USA. 2014;111(47):16814-16819. doi:10.1073/pnas.1414189111 3. Flynn R, Paz K, Du J, et al. Targeted Rho-associated kinase 2 inhibition suppresses murine and human chronic GVHD through a Stat3-dependent mechanism. Blood. 2016;127(17):2144-2154. doi:10.1182/blood-2015-10-678706 4. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Hematopoietic Cell Transplantation (HCT). V.1.2022. © National Comprehensive Cancer Network, Inc. 2022. All rights reserved. Accessed April 19, 2022. To view the most recent and complete version of the guideline, go online to NCCN.org

© 2023 Kadmon Pharmaceuticals, LLC.
All Rights Reserved.
This site is intended for use by US Health Care Professionals only.
MAT-US-2201620-v2.0-12/2023   
Last updated: December 2023

Usage of cookies

This website uses cookies to track its audience and improve its content. By continuing to browse this website, you agree to the use of such cookies.

More information on cookies

Please verify that you are a US health care professional

This information is intended for US health care professionals.

I am a US
professional.